PDCD1 and renal cell carcinoma: Immunotherapeutic agents targeting PD-1/ PD-L1, such as Nivolumab and Ipilimumab, have demonstrated superior long-term survival benefits compared with sunitinib, a TKIs, in untreated intermediate/low-risk advanced RCC patients (Boussios et al., 2023).